7 Days
Source:
المشهد
Source: المشهد
7 Daysالمشهد
Source: المشهد
7 DaysReady to play
Ready to play
A mid-stage clinical trial found that alternating Votrient and Avastin may prolong survival for some people newly diagnosed with advanced clear-cell kidney cancer. Among 51 patients, median overall survival was 63.2 months, and median progression-free survival was 24.8 months—compared with overall survival of 28.4 to 29.3 months for Votrient alone. Among the 33 patients in the favorable-risk group, median overall survival was 76.9 months and median progression-free survival was 28.5 months. The study lead said the treatment’s benefit for this group may match or exceed that of current immunotherapy combinations, at a lower cost.
Notice: This Is an AI-Generated Summary
Comments (0)